skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Next-generation anthracycline for the management of small cell lung cancer: focus on amrubicin

Review

(3516) Views  (712) Full article downloads

Authors: Michiko Yamamoto, Akira Takakura, Noriyuki Masuda

Published Date September 2008 Volume 2008:2 Pages 189 - 192
DOI: http://dx.doi.org/10.2147/DDDT.S3972

Michiko Yamamoto, Akira Takakura, Noriyuki Masuda

Department of Respiratory Medicine, Kitasato University School of Medicine, Kitasato, Japan

Abstract: Amrubicin is a totally synthetic anthracycline anticancer agent that acts as a potent topoisomerase II inhibitor. Amrubicin has been approved in Japan for the treatment of lung cancer, and the results from clinical studies of amrubicin as a single agent or as part of combination regimens for lung cancer, particularly for small cell lung cancer, conducted in Japan and overseas have been promising. Amrubicin should be included among new treatment strategies especially for chemoresistant patients. Here, preclinical, pharmacological, and clinical data on the use of amrubicin for the treatment of small cell lung cancer are reviewed.

Keywords: amrubicin, anthracycline, small-cell lung cancer, extensive disease






 

Other articles by Dr Noriyuki Masuda



Readers of this article also read:

Structure-based design of anticancer prodrug PABA/NO
Drug design with Cdc7 kinase: a potential novel cancer therapy target
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Long-term disease-free survivor of metastatic large-cell neuroendocrine carcinoma of the lung treated with amrubicin and irinotecan
The pathophysiology of bronchiectasis
Health literacy and health seeking behavior among older men in a middle-income nation
Retinal nerve fiber layer evaluation in multiple sclerosis with spectral domain optical coherence tomography
A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCG-refractory and BCG-intolerant patients
Erratum
Successful mobilization of peripheral blood stem cells in children with cancer using plerixafor (Mozobil™) and granulocyte-colony stimulating factor
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University